AbbVie reported net revenues of $14.46 billion, surpassing expectations. Sales increased across immunology, oncology, and neuroscience products. The company raised its 2024 adjusted EPS guidance. AbbVie also decided to halt development of an Alzheimer's drug.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing